Protein & Antibody World Congress 2023 Europe

Hilton, London, Kensington, London, United Kingdom
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Protein & Antibody World Congress 2023 Europe

Full Program Available ShortlyĀ 

GAIN LATEST INSIGHTS ON:

WHO SHOULD ATTEND?

Network with scientists, analysts, senior VPs, Heads, Directors and Managers of leading
biopharmaceutical and biotech companies, diagnostics, government, CRO and Solution providers whose responsibilities includes;

0 +
speakers
0
days Congress
0 +
Presentation
0 +
Attendees

Key Industry Expert Speakers

2023 Speakers - will be uploaded shortly.

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Available Shortly

Senior Representative

Coming Soon

Schedule

Content Rich Program Agenda!Ā  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

  • Potential applications on cellular pathway alteration at the protein level: targeted protein sequestration, protein recruitment, protein degradation, and selective
    inhibition of binding interfaces
  • Biochemical, genetic, and technological challenges in genetic code engineering

PROTEIN AND ANTIBODY TECHNOLOGY

  • Recent advances in computational/AI-based techniques for antibody engineering and discovery
  • AI methods relevant for antibody development
  • Computational antibody design procedures with emphasis to machine learning
  • Examining the current biological and engineering challenges facing the biomanufacturing of antibodies
  • Emerging technologies to reduce biomanufacturing challenges.
  • Innovations in process analytical technologies and single use technologies to improve current performance of mAb production processes.
  • Docking setup using the wrapper code approach to optimize the DOCK program for large-scale computation as well as docking analysis using variance and promiscuity
  • Relevance of Small angle X-ray scattering (SAXS) for quantifying conformational flexibility in proteins
  • Feasibility of MARS for the measurement of both protein purity-related and formulation-related PQAs
  • Potential to be a powerful methodology to improve the efficiency of biopharmaceutical development and manufacturing

PROTEIN AND ANTIBODY METHODOLOGY

  • Comprehensive overview of validated, forgotten and newly develop payloads with diverse procedures of action.
  • Key role of Payload Diversification in the field of future ADC development
  • Advantages of payloads and benefits of payload diversification
  • Evolution of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) targets for cancer therapy
  • Use of scTRAIL and associated peptide linkers as promising strategy for antitumor therapeutics
  • Steps in the process of antibody discovery and development
  • Differences in developability analyses in discovery and development stages
  • Developability-related considerations and assessment at the discovery stage
  • Analysis and optimization of developability-related attributes
  • Carbohydrates as promising targets for vaccine development against infectious disease
  • Strategies on overcoming challenges carbohydrate-based vaccine design and development approaches targeting cancer and other diseases
  • How can general protein language models efficiently evolve human antibodies?
  • Could these models be applicable to evolving more unnatural, de novo designed proteins
  • Comparison to other sequence-based methods
  • Computational efficiency of this approach
  • Leveraging data beyond protein sequence information including protein structure information and binding affinity data to further improve the outcome
  • ADCs role in the new wave of investigational drug candidates in this field
  • Impact of ADCs on technology development using better linker/payload chemistry and improved processes

PROTEIN AND ANTIBODY ENGINEERING

  • ADCs role in the new wave of investigational drug candidates in this field
  • Impact of ADCs on technology development using better linker/payload chemistry and improved processes
  • Validation testing and reporting strategies and tools
  • Influence of interfering factors known to cause false ADA positive signals.
  • Framework and a concise reporting structure for NAb assay validations.
  • The need for industry-wide alignment that will streamline the review process by regulatory agencies
  • Lactic acid bacteria as promising vectors of choice to deliver active molecules to mucosal tissues
  • Recent developments on surface-display technologies important for potential industrial applications of lactic acid bacteria
  • Recent development of drug discovery targeting ā€œundruggableā€ proteins and their application in clinic.
  • Opportunities for undruggable targets in treatment of human diseases
  • Innovative approaches and cutting-edge technologies resulting in several approved drugs and emerging potent chemical entities
  • Key considerations that drive the chemical design of protein-based therapeutics
  • Well-established and emerging structural and chemical design strategies that have enabled paradigm shift in diseases treatment.
  • Areas that need further development to realize the full potential of these molecules
  • Review of the development of mRNA peptide display
  • How is this technology applied in Drug discovery?
  • Addressing the Challenges and future outlook
  • Implications of mesotrypsin up-regulation in cancer progression
  • Recognition of mesotrypsinā€™s unique capability on cleavage and inactivation of proteinaceous inhibitors for development of anticancer protein therapeutics
  • Overview of the many ways in which ligands can affect GPCR function.
  • How this information can be used to develop novel therapeutics against various GPCR targets.
  • Challenges and promising opportunities.
  • New innovative strategies and tools needed to design, develop, and pharmacologically characterize novel GPCR ligands with the aim of creating better
    and more specific drugs.
  • Therapeutic antibody development process overview
  • Key parameters influencing therapeutic antibody development.
  • Innovative tools and methods used to assess product purity and safety throughout therapeutic antibody development.
  • Importance of successfully demonstrating safety and efficacy of therapeutic antibodies for regulatory approval and market authorization

Protein & Antibody World Congress 2023 Europe

Newsletter Sign Up

No Spam - You will only receive relevant information on Real-World Evidence, and event updates

Delegate Tickets

Group Discounts Are Also Available

Advocates / Patient / Non Profit

Full Price
Ā£
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Standard Registration Rate

Full Price
Ā£
  • Full Access - 2 Day Conference
  • All Day Refreshments & Lunches
  • Conference Documentations
  • Networking Drinks Reception

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Eventsā€¦ very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotechā€¦ we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now!Ā 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.Ā 

Location

Scroll to Top